Company: PIII
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001832511-25-000013
Chunk: 157

Company: P3 Health Partners Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 157
---
. Pursuant to the VGS 5 Subordination Agreement, VGS 5 agreed to subordinate its right of payment under the VGS 5 Promissory Note to the right of payment and security interests of the lenders under the Term Loan Facility. The terms of the VGS 5 Subordination Agreement will effectively require P3 LLC to pay all interest under the VGS 5 Promissory Note in-kind.Amendment to Term Loan Agreement and Consent In connection with the transactions described above, on May 29, 2025, P3 LLC entered into the Ninth Amendment to the Term Loan Agreement (the “Ninth Amendment”), by and among P3 LLC, as borrower, the subsidiary guarantors 

P3 Health Partners Inc. | Q2 2025 Form 10-Q | 17

party thereto, the lenders from time to time party thereto and CRG, as administrative agent and collateral agent. The Ninth Amendment permits the issuance of the VGS 5 Promissory Note and the entry into the VGS 5 Subordination Agreement.

Note 9: Net Loss per ShareThe following table provides the computation of basic and diluted net loss per share:Three Months Ended June 30,Six Months Ended June 30,2025202420252024(in thousands, except per share data)Numerator–basic:Net loss attributable to Class A common stockholders–basic$(20,362)$(12,020)$(40,842)$(30,720)Numerator–diluted:Net loss attributable to Class A common stockholders–basic$(20,362)$(12,020)$(40,842)$(30,720)Effective of dilutive securities:Liability-classified warrants— (8,779)— (8,779)Net loss attributable to Class A common stockholders–diluted$(20,362)$(20,799)$(40,842)$(39,499)Denominator–basic:Weighted average Class A common shares outstanding–basic3,267 2,732 3,263 2,556 Net loss per share attributable to Class A common stockholders–basic$(6.23)$(4.40)$(12.52)$(12.02)Denominator–diluted:Weighted average Class A common shares outstanding–basic3,267 2,732 3,263 2,556 Weighted average effect of dilutive securities:Liability-classified warrants